Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global steroids for pets market was valued at USD 1.16 billion in 2025 and is projected to reach USD 2.04 billion by 2034, exhibiting a CAGR of 6.7% during the forecast period. This growth trajectory is driven by the increasing pet healthcare expenditure and rising demand for specialized veterinary treatments.
Steroids for pets are synthetic compounds administered to companion animals for therapeutic purposes, primarily to manage inflammation, allergies, and autoimmune disorders. Key categories include glucocorticoids like prednisone and dexamethasone, as well as sex hormones such as estradiol. These medications can be delivered through oral, topical, or injectable formulations, with dosing regimens tailored to species-specific metabolic requirements.
The market expansion is fueled by multiple factors, including the humanization of pets and consequent willingness to invest in advanced veterinary care. Recent data highlights this trend: The UK's veterinary service expenditures surged 54% to 4 billion between 2015-2021, while China's pet medical market reached 67.5 billion in 2022. Furthermore, with 13.09 million pets entering geriatric stages in China alone, the demand for chronic condition management therapies like steroids is accelerating. Leading players such as Zoetis and Merck are actively expanding their veterinary pharmaceutical portfolios to capitalize on this demand.
Rising Prevalence of Chronic Conditions in Pets
The increasing incidence of chronic ailments such as arthritis, allergies, and autoimmune diseases in companion animals is driving demand for steroid-based treatments. Approximately 20% of dogs and 15% of cats develop chronic conditions requiring long-term medication.
Growing Pet Humanization Trend
Pet owners are increasingly willing to invest in advanced medical treatments, with veterinary steroid expenditures growing at an annual rate of 6-8% in developed markets. This mirrors the broader humanization trend where pets are considered family members.
"The pet steroid market has shown particular strength in dermatological applications, accounting for nearly 40% of all veterinary steroid prescriptions."
Additionally, rising disposable incomes in emerging economies are enabling more pet owners to afford specialized veterinary care that includes steroidal treatments.
MARKET CHALLENGES
Regulatory Hurdles in Veterinary Pharmaceuticals
Stringent approval processes and post-market surveillance requirements for veterinary steroids create significant barriers to market entry, often requiring 3-5 years for new product approvals.
Other Challenges
Side Effect Management
Concerns about potential adverse effects (reported in 5-12% of cases) including increased thirst, appetite changes, and immune suppression continue to impact prescribing decisions.
Generic Competition
The increasing availability of generic corticosteroids is putting downward pressure on prices, particularly in the prednisolone and dexamethasone segments.
Growing Preference for Alternative Therapies
About 15-20% of veterinary practitioners now recommend non-steroidal options first for chronic conditions, particularly in cases where long-term steroid use might be contraindicated.
Development of Targeted Steroid Formulations
There is significant unmet need for condition-specific steroid preparations in veterinary medicine, particularly for feline applications where conventional steroids show variable efficacy.
Expansion in Emerging Markets
Countries experiencing rapid growth in companion animal populations coupled with improving veterinary infrastructure present substantial opportunities. The Asia-Pacific veterinary steroid market is projected to grow at 9% CAGR through 2028.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Prednisone remains the most widely prescribed steroid for pets due to its broad anti-inflammatory properties and established safety profile in veterinary medicine. The market shows notable preference for intermediate-acting corticosteroids that balance therapeutic efficacy with manageable side effect profiles. |
| By Application |
|
Dog treatments dominate the segment as canine patients have higher incidence rates of steroid-responsive conditions like allergies and autoimmune disorders. The cat segment shows significant therapeutic challenges due to feline-specific metabolic sensitivities requiring specialized dosing regimens. |
| By End User |
|
Veterinary Hospitals account for the majority of steroid administration, benefitting from specialized equipment and staff trained in managing complex steroid therapies. The home care segment shows growing importance for chronic conditions requiring long-term treatment management. |
| By Administration Route |
|
Oral formulations maintain market preference due to convenience in administration and precise dosing capabilities. Injectable steroids demonstrate critical importance for emergency cases, while topical applications show strong growth potential for dermatological conditions. |
| By Therapeutic Use |
|
Anti-inflammatory applications constitute the primary use case, addressing widespread conditions like arthritis and dermatitis. The immunosuppressive segment is gaining traction for treating autoimmune diseases in pets, particularly as diagnostic capabilities improve in veterinary medicine. |
Pharmaceutical Giants and Veterinary Specialists Dominate Steroids for Pets Sector
The global steroids for pets market is dominated by established pharmaceutical companies with strong veterinary divisions, led by Zoetis, Boehringer Ingelheim, and Merck Animal Health. These industry leaders account for over 40% of market share, offering comprehensive steroid portfolios across various administration routes. The market structure shows consolidation among top players with significant R&D capabilities, while mid-sized veterinary pharmaceutical companies focus on regional markets and specialized formulations.
Niche players like Virbac and Dechra Pharmaceuticals have carved substantial market positions through specialized steroid formulations for companion animals. Emerging biotechnology firms are introducing novel delivery systems and combination therapies, particularly in markets with growing pet healthcare expenditure like China and India. The competitive landscape also includes compounding pharmacies serving specific veterinary needs not addressed by mass-market products.
List of Key Steroids for Pets Companies ProfiledZoetis Inc.
Merck Animal Health
Vetoquinol SA
Bimeda Animal Health
Trudell Animal Health
Chanelle Pharma
Elanco Animal Health
Norbrook Laboratories
Huvepharma
Jurox Animal Health
The global steroids for pets market is experiencing significant growth, valued at $XX million in 2025 and projected to reach $XX million by 2034 with a CAGR of X%. This expansion correlates directly with the increasing population of aging pets worldwide. In China alone, over 13 million pets entered middle or old age in 2023, driving demand for veterinary medications including corticosteroids like prednisone and dexamethasone.
Other TrendsMarket Segmentation by Product Type
Prednisone currently dominates the market with XX% share, followed by prednisolone (XX%) and dexamethasone (XX%). Oral formulations remain most prevalent due to ease of administration, though injectable steroids maintain importance for acute conditions. Regional preferences show North America favoring shorter-acting steroids while European markets demonstrate higher adoption of sustained-release formulations.
Regional Market Development PatternsNorth America commands XX% of the global market share, with the Asia-Pacific region showing the highest growth potential at XX% CAGR. China's pet medical market has expanded to XX billion, representing XX% of the total pet industry. Europe maintains steady growth, with UK veterinary spending increasing 54% from 2015-2021, reaching 4 billion annually.
Industry Consolidation and Key Players
The market remains concentrated with Zoetis, Merck, and Boehringer Ingelheim collectively holding over XX% market share. Recent developments include mergers among mid-tier players like Dechra Pharmaceuticals and Bimeda Animal Health, aimed at expanding product portfolios. Approximately 40% of pet hospitals report increased annual turnover, with growth rates between 4-11%, creating further demand for veterinary pharmaceuticals.
Regional Analysis: Steroids for Pets MarketEurope
Europe represents the second-largest market for steroids in veterinary medicine, with stringent regulations governing their use. The region sees higher adoption of alternative therapies alongside steroids, particularly in countries like Germany and the UK where holistic pet care is popular. Northern European countries show higher steroid usage for autoimmune conditions due to genetic predispositions in certain breeds. Eastern Europe is emerging as a growth area with improving veterinary infrastructure.
Asia-Pacific
The Asia-Pacific steroids for pets market is growing rapidly, driven by increasing pet adoption and rising incomes. Japan and Australia lead in steroid usage, while developing markets focus on essential veterinary medicines. Cultural perceptions about steroid use in pets vary significantly across countries, with some markets showing resistance. Increasing pet insurance penetration in urban areas supports market growth.
South America
South America shows uneven steroid adoption, with Brazil and Argentina as relatively developed markets. Economic fluctuations impact affordability of long-term steroid treatments. There's growing interest in locally manufactured steroid formulations to reduce costs. Veterinary education about proper steroid use is improving but remains inconsistent across the region.
Middle East & Africa
This region exhibits the lowest steroid adoption rates, concentrated in affluent urban areas and expatriate communities. Import dependency makes steroids relatively expensive. Traditional remedies often compete with pharmaceutical treatments. Some countries restrict certain steroid formulations for religious or cultural reasons, creating variations in market accessibility.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252034. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging pharmaceutical technologies
Sustainability initiatives in veterinary medicine
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Regulatory trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Veterinary pharmaceutical companies
Animal healthcare providers
Pet care product manufacturers
Investors, consultants, and policy makers
-> Global steroids for pets market was valued at USD 1.16 billion in 2025 and is projected to reach USD 2.04 billion by 2034.
Which key companies operate in Global Steroids for Pets Market?
-> Key players include Boehringer Ingelheim, Zoetis, Merck, Virbac, and Vetoquinol, among others.
-> Key growth drivers include rising pet healthcare expenditure, increasing pet humanization, and growing geriatric pet population.
-> North America currently leads the market, while Asia-Pacific shows the fastest growth potential.
-> Emerging trends include species-specific formulations, extended-release steroids, and digital pet health monitoring.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates